摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Clinafloxacin hydrochloride, (R)- | 186802-93-7

中文名称
——
中文别名
——
英文名称
Clinafloxacin hydrochloride, (R)-
英文别名
7-[(3R)-3-aminopyrrolidin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid;hydrochloride
Clinafloxacin hydrochloride, (R)-化学式
CAS
186802-93-7
化学式
C17H18Cl2FN3O3
mdl
——
分子量
402.2
InChiKey
BMACYHMTJHBPOX-DDWIOCJRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.79
  • 重原子数:
    26
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    86.9
  • 氢给体数:
    3
  • 氢受体数:
    7

文献信息

  • Rifamycin C-11 oxime derivatives effective against drug-resistant microbes
    申请人:Li Jing
    公开号:US20050203076A1
    公开(公告)日:2005-09-15
    The invention relates to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the rifamycin derivatives having an oxime group at the C-11 position.
    该发明涉及具有抗微生物活性的利福霉素生物,包括针对耐药微生物的活性,具体来说,具有在C-11位置的基的利福霉素生物
  • [EN] RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES<br/>[FR] DERIVES DE RIFAMYCINE IMINO EFFICACES CONTRES DES MICROBES PHARMACORESISTANTS
    申请人:CUMBRE INC
    公开号:WO2005070941A1
    公开(公告)日:2005-08-04
    The present invention relates to rifamycin 3-iminomethylenyl (-CH=N-) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (-CH=N-) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.
    本发明涉及具有抗微生物活性的利福霉素3-亚甲基亚胺基(-CH=N-)衍生物,包括对耐药微生物的活性。所述的利福霉素生物具有一个利福霉素基团,通过亚甲基亚胺基(-CH=N-)在利福霉素基团的C-3碳上与一个连接剂共价连接,而连接剂又与DNA旋转酶和拓扑异构酶IV抑制剂家族中的奎诺酮结构或其药效团共价连接。这种创新的利福霉素是新颖的,并对利福平环丙沙星耐药微生物表现出活性。
  • RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES
    申请人:Cumbre Pharmaceuticals Inc.
    公开号:EP1723150A1
    公开(公告)日:2006-11-22
  • US7256187B2
    申请人:——
    公开号:US7256187B2
    公开(公告)日:2007-08-14
查看更多